AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24342746 — intervention group
Group type: EXPERIMENTAL
Intervention: Hépar 1 group (1 L Hépar and 0.5 L natural low‐mineral water daily)
Number of subjects: 244
Study 24342746 — intervention group
Group type: EXPERIMENTAL
Intervention: Hépar 0.5 group (0.5 L Hépar and 1 L natural low‐mineral water daily)
Number of subjects: 244
Study 24342746 — intervention group
Group type: COMPARATOR
Intervention: Control group (1.5 L natural low‐mineral water daily)
Number of subjects: 244
Study 22369335 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed interventions observed by children
Number of subjects: 24
Study 22369335 — intervention group
Group type: COMPARATOR
Intervention: Temporal reversal of cause and effect
Number of subjects: 24
Study 22369335 — intervention group
Group type: EXPERIMENTAL
Intervention: Human interventions leading to covariations
Number of subjects: 24
Study 19013613 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroplastique injection
Number of subjects: 247
Study 19013613 — intervention group
Group type: COMPARATOR
Intervention: Contigen injection
Number of subjects: 247
Study 20439193 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT + temozolomide (75 mg/m2/day for 21 or 28 days)
Number of subjects: 95
Study 20439193 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone (30 Gy in 10 fractions)
Number of subjects: 95
Study 15607839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tincture of opium (TO)
Number of subjects: 33
Study 15607839 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (MO)
Number of subjects: 33
Study 12654206 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 378
Study 12654206 — intervention group
Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 378
Study 9610646 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural home care intervention program
Number of subjects: 0
Study 9610646 — intervention group
Group type: COMPARATOR
Intervention: Standard care programs
Number of subjects: 0
Study 8146996 — intervention group
Group type: EXPERIMENTAL
Intervention: iodine brine concentrate (2 x 100 ml, daily iodine uptake approximately 9 mg)
Number of subjects: 61
Study 8146996 — intervention group
Group type: COMPARATOR
Intervention: isotonic NaCl
Number of subjects: 61
Study 31615318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics + anti-inflammatory + purified micronized flavonoid fraction (Group 2)
Number of subjects: 127
Study 31615318 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified micronized flavonoid fraction (Group 3)
Number of subjects: 127
Study 31615318 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics + anti-inflammatory + alpha-blocker (Group 1)
Number of subjects: 127
Study 29705375 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive intervention (median time to intervention 1.4 hours)
Number of subjects: 323
Study 29705375 — intervention group
Group type: COMPARATOR
Intervention: Delayed invasive strategy (median time to intervention 61.0 hours)
Number of subjects: 323
Study 29705375 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive intervention
Number of subjects: 323
Study 29705375 — intervention group
Group type: COMPARATOR
Intervention: Delayed invasive strategy
Number of subjects: 323
Study 27846165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral laparoscopic splenectomy (LLS)
Number of subjects: 80
Study 27846165 — intervention group
Group type: COMPARATOR
Intervention: Anterior laparoscopic splenectomy (ALS)
Number of subjects: 80
Study 24448738 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) intervention
Number of subjects: 7166
Study 24448738 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7166
Study 21996130 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleable protein matrix (MPM) from whey in low-fat yoghurt (150 g, two servings daily for 3 months)
Number of subjects: 197
Study 21996130 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleable protein matrix (MPM) from whey in low-fat yoghurt
Number of subjects: 197
Study 21996130 — intervention group
Group type: COMPARATOR
Intervention: Placebo yoghurt (matching control, identical in protein content 15 g/d)
Number of subjects: 197
Study 20520295 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-based ratings
Number of subjects: 100
Study 20520295 — intervention group
Group type: COMPARATOR
Intervention: Centralized ratings
Number of subjects: 100
Study 18535870 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 60
Study 18535870 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study 15838757 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletic children (sportsmen)
Number of subjects: 177
Study 15838757 — intervention group
Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 177
Study 15838757 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer players and athletes
Number of subjects: 177
Study 15838757 — intervention group
Group type: EXPERIMENTAL
Intervention: Judokas and wrestlers
Number of subjects: 177
Study 12895195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.2 mg daily)
Number of subjects: 10
Study 12895195 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 10
Study 10373050 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (5 mg . kg(‐1) caffeine + 1 mg . kg(‐1) ephedrine)
Number of subjects: 10
Study 10373050 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 10
Study 10373050 — intervention group
Group type: COMPARATOR
Intervention: Control (Cont)
Number of subjects: 10
Study 10373050 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E
Number of subjects: 10
Study 8714153 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD-RT23
Number of subjects: 830
Study 8714153 — intervention group
Group type: COMPARATOR
Intervention: PPD-CT68
Number of subjects: 830
Study 2049365 — intervention group
Group type: EXPERIMENTAL
Intervention: AD patients
Number of subjects: 33
Study 2049365 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 33
Study 6407501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (maximum 300 mg daily)
Number of subjects: 151
Study 6407501 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (maximum 200 mg daily)
Number of subjects: 151
Study 6407501 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 151
Study 6407501 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 151
Study 30726897 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 29924912 — intervention group
Group type: EXPERIMENTAL
Intervention: One-way SMS
Number of subjects: 300
Study 29924912 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way SMS
Number of subjects: 300
Study 29924912 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 300
Study 27472747 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Approach Therapy (SAT)
Number of subjects: 29
Study 27472747 — intervention group
Group type: COMPARATOR
Intervention: PTSD family education intervention
Number of subjects: 29
Study 24801219 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRC (compound Congrongyizhi Capsule) treatment
Number of subjects: 41
Study 24801219 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 41
Study 24801219 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 41
Study 23039709 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified neonatal resuscitation protocol (Helping Babies Breathe)
Number of subjects: 0
Study 23039709 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement process cycle introducing the neonatal resuscitation protocol
Number of subjects: 0
Study 20490876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar support
Number of subjects: 0
Study 17592393 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation exercises
Number of subjects: 87
Study 17592393 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercises
Number of subjects: 87
Study 15701665 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalization
Number of subjects: 202
Study 15701665 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 202
Study 15701665 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation
Number of subjects: 202
Study 15701665 — intervention group
Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 202
Study 11327244 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory activity monitor (Dynaport® ADL monitor)
Number of subjects: 41
Study 9688376 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ferric hyaluronate adhesion prevention gel
Number of subjects: 0
Study 9688376 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (Control)
Number of subjects: 0
Study 8012141 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 0.1% eyedrops and prednisolone 1% eyedrops
Number of subjects: 40
Study 8012141 — intervention group
Group type: COMPARATOR
Intervention: indomethacin 1% eyedrops and prednisolone 1% eyedrops
Number of subjects: 40
Study 2684659 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with morphine
Number of subjects: 30
Study 2684659 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia without morphine
Number of subjects: 30
Study 2684659 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study 1099895 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron treatment
Number of subjects: 29
Study 1099895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1099895 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 30160373 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal depression screening and intervention (six-session group intervention)
Number of subjects: 352
Study 30160373 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 352
Study 30160373 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal depression screening and intervention (husband participation in Session 6)
Number of subjects: 352
Study 29091979 — intervention group
Group type: EXPERIMENTAL
Intervention: PlanYourLifespan.org (PYL)
Number of subjects: 385
Study 29091979 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 385
Study 25827024 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial head replacement (n = 20)
Number of subjects: 39
Study 25827024 — intervention group
Group type: COMPARATOR
Intervention: Radial head repair (n = 19)
Number of subjects: 39
Study 23688146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for childhood anxiety
Number of subjects: 66
Study 21855408 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening bright light exposure (∼4000 lux) for 45 minutes daily
Number of subjects: 32
Study 21855408 — intervention group
Group type: COMPARATOR
Intervention: Morning bright light exposure (∼4000 lux) for 45 minutes daily
Number of subjects: 32
Study 19586960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) followed by primary percutaneous coronary intervention (PCI)
Number of subjects: 1667
Study 19586960 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI alone
Number of subjects: 1667
Study 19586960 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-pre-treated patients without reperfusion (TIMI 0-1) after PCI
Number of subjects: 1667
Study 19586960 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP levels
Number of subjects: 1667
Study 17583796 — intervention group
Group type: EXPERIMENTAL
Intervention: Palaeolithic diet
Number of subjects: 29
Study 17583796 — intervention group
Group type: COMPARATOR
Intervention: Consensus (Mediterranean-like) diet
Number of subjects: 29
Study 15271117 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for symptomatic DVT identified through logistic regression analysis
Number of subjects: 620
Study 15271117 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined score of risk factors for DVT
Number of subjects: 620
Study 11343039 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 63
Study 11343039 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 63
Study 11343039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9169338 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% crude coal tar (CCT) ointment
Number of subjects: 30
Study 9169338 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum and salicylic acid
Number of subjects: 30
Study 8228797 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 x 10(6) IU 1 h‐1)
Number of subjects: 20
Study 8228797 — intervention group
Group type: COMPARATOR
Intervention: tPA (100 mg 3 h‐1)
Number of subjects: 20
Study 8228797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after 24 h on acetylsalicylic acid)
Number of subjects: 20
Study 8228797 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20
Study 8228797 — intervention group
Group type: COMPARATOR
Intervention: tPA
Number of subjects: 20
Study 2938472 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 41
Study 2938472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31703672 — intervention group
Group type: EXPERIMENTAL
Intervention: Extemporaneous compounding practices in pharmacies
Number of subjects: 431
Study 31703672 — intervention group
Group type: COMPARATOR
Intervention: Reasons for not providing extemporaneous compounding services
Number of subjects: 431
Study 31703672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources for compounding protocols
Number of subjects: 431
Study 31703672 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of compounded medications expiration date
Number of subjects: 431
Study 31703672 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonly compounded dosage forms
Number of subjects: 431
Study 31703672 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation of sterile products
Number of subjects: 431
Study 29226630 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling combined with platelet-rich plasma (PRP)
Number of subjects: 24
Study 29226630 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling combined with trichloroacetic acid (TCA) 15% peeling
Number of subjects: 24
Study 29226630 — intervention group
Group type: COMPARATOR
Intervention: Microneedling alone (dermaroller)
Number of subjects: 24
Study 26620191 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO risk genotype (AA)
Number of subjects: 0
Study 26620191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest fried food consumption with two copies of FTO risk variant
Number of subjects: 0
Study 26620191 — intervention group
Group type: COMPARATOR
Intervention: No risk alleles with lowest fried food consumption
Number of subjects: 0
Study 24809142 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (MREE <90%)
Number of subjects: 158
Study 24809142 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (MREE 90%-110%)
Number of subjects: 158
Study 24809142 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (MREE >110%)
Number of subjects: 158
Study 22426910 — intervention group
Group type: EXPERIMENTAL
Intervention: Acaricides
Number of subjects: 82
Study 22426910 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 82
Study 19938710 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-oriented infusion therapy with monitoring of central hemodynamic parameters and passive leg raising test
Number of subjects: 47
Study 19938710 — intervention group
Group type: COMPARATOR
Intervention: Standard infusion therapy (a combination of colloids and crystalloids (1:1) at a rate of 6‐7 ml/kg/h)
Number of subjects: 47
Study 17466815 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphase Optimization Strategy (MOST)
Number of subjects: 0
Study 17466815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Multiple Assignment Randomized Trial (SMART)
Number of subjects: 0
Study 15951872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH) - autologous blood 15 mL kg(‐1) withdrawn and replaced by 6% hydroxyethylstarch (HES)
Number of subjects: 30
Study 15951872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypervolemic hemodilution (HHD) - HES administered without removal of any autologous blood
Number of subjects: 30
Study 15951872 — intervention group
Group type: COMPARATOR
Intervention: Control group - no hemodilution
Number of subjects: 30
Study 12831588 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose (SD) protocol of cetrorelix (3 mg); n = 541
Number of subjects: 1607
Study 12831588 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose (MD) protocol of cetrorelix (0.25 mg/day); n = 1066
Number of subjects: 1607
Study 12831588 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned);
Number of subjects: 1607
Study 10382927 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 1 ml saline per nerve root sleeve (group A)
Number of subjects: 60
Study 10382927 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml bupivacaine 0.5% combined with 40 mg methylprednisolone solution (group B)
Number of subjects: 60
Study 10382927 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml bupivacaine 0.5% combined with 1500 units hyaluronidase and 40 mg methylprednisolone solution (group C)
Number of subjects: 60
Study 8887586 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural surfactant treatment
Number of subjects: 11
Study 1428783 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CE)
Number of subjects: 0
Study 6321673 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy and chemotherapy (group R, 76 patients)
Number of subjects: 164
Study 6321673 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy (group C, 88 patients)
Number of subjects: 164
Study 6321673 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy (group C)
Number of subjects: 164
Study 3948591 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental intervention
Number of subjects: 0
Study 3948591 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-infant intervention
Number of subjects: 0
Study 3948591 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (preterm)
Number of subjects: 0
Study 3948591 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (full-term)
Number of subjects: 0
Study 30203479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer intervention for 12 weeks
Number of subjects: 1020
Study 27613170 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic-delivered adenosine (PARA)
Number of subjects: 86
Study 27613170 — intervention group
Group type: COMPARATOR
Intervention: Conventional emergency department (ED) care
Number of subjects: 86
Study 25747677 — intervention group
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent implantation
Number of subjects: 65
Study 23807371 — intervention group
Group type: COMPARATOR
Intervention: Sham with prompt laser
Number of subjects: 0
Study 23807371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab with prompt laser
Number of subjects: 0
Study 23807371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab with deferred laser
Number of subjects: 0
Study 23807371 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone with prompt laser
Number of subjects: 0
Study 23807371 — intervention group
Group type: COMPARATOR
Intervention: Sham with prompt laser (for eyes with PDR at baseline)
Number of subjects: 0
Study 23807371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab with prompt laser (for eyes with PDR at baseline)
Number of subjects: 0
Study 23807371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab with deferred laser (for eyes with PDR at baseline)
Number of subjects: 0
Study 23807371 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone with prompt laser (for eyes with PDR at baseline)
Number of subjects: 0
Study 21091899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscopy (CCF)
Number of subjects: 250
Study 21091899 — intervention group
Group type: COMPARATOR
Intervention: Normal colonoscopy without a cap (NCCF)
Number of subjects: 250
Study 18201212 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.25 mg/day
Number of subjects: 39
Study 18201212 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.9 mg/day
Number of subjects: 39
Study 18201212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16771811 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC and BAS
Number of subjects: 72
Study 16771811 — intervention group
Group type: COMPARATOR
Intervention: TAC and steroids
Number of subjects: 72
Study 14696679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unkei-to
Number of subjects: 0
Study 10926623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Salbutamol (12 mg/day for 3 weeks)
Number of subjects: 8
Study 10926623 — intervention group
Group type: COMPARATOR
Intervention: Gelatin placebo
Number of subjects: 8
Study 8610732 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-initiated 'most important' recommendations
Number of subjects: 139
Study 8610732 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-initiated 'major' recommendations
Number of subjects: 139
Study 8610732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient adherence to physician-initiated 'most important' recommendations
Number of subjects: 139
Study 8610732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient adherence to physician-initiated 'major' recommendations
Number of subjects: 139
Study 8610732 — intervention group
Group type: EXPERIMENTAL
Intervention: Health maintenance organization (HMO) status of the patient
Number of subjects: 139